Nathan Moore

Nathan Moore, PhD, currently serves as Director and Head of Research Technology and Digital Transformation at Takeda, overseeing initiatives in cell therapy technology and digital transformation since August 2019. Previously, Nathan held positions at Draper, where responsibilities included leading projects in immuno-oncology and cell bioprocessing, as well as at Acetylon Pharmaceuticals, focusing on preclinical development of targeted HDAC inhibitors. Nathan began a research fellowship at Dana-Farber Cancer Institute and Harvard Medical School, contributing to pediatric oncology research and the discovery of novel therapeutics targeting ALK receptor tyrosine kinases. Nathan earned a PhD in Biomedical Sciences from UMass Chan Medical School and a BS in Molecular Biology from Pacific University.